John Lee, MD
Ophthalmology · Hemet, CANPI 1568637361
Payments from drug & device makers
Across 177 payments — averaging $21.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$2K
- AbbVie$578
- Aerie Pharmaceuticals, Inc.$355
- Sight Sciences, Inc.$258
- Bausch & Lomb Americas Inc.$201
- Harrow Eye, LLC$102
- plus $666 from 15 others
What the payments were for
- Food & beverage$3,747100%
- Education$130%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 72 | $1,601 |
| AbbVie(2 entities) | 30 | $578 |
| Aerie Pharmaceuticals, Inc. | 21 | $355 |
| Sight Sciences, Inc. | 11 | $258 |
| Bausch & Lomb Americas Inc. | 10 | $201 |
| Harrow Eye, LLC | 3 | $102 |
| Glaukos Corporation | 3 | $101 |
| Sun Pharmaceutical Industries Inc. | 5 | $78 |
| Amgen(2 entities) | 4 | $74 |
| Mallinckrodt Hospital Products Inc. | 2 | $64 |
| Tarsus Pharmaceuticals, Inc. | 2 | $62 |
| Dompe US, Inc. | 3 | $60 |
| Ivantis, Inc | 2 | $49 |
| Eyevance Pharmaceuticals LLC | 2 | $37 |
| Vanda Pharmaceuticals Inc. | 1 | $28 |
| Oyster Point Pharma, Inc. | 1 | $27 |
| Kala Pharmaceuticals, Inc. | 1 | $21 |
| Thea Pharma Inc. | 1 | $20 |
| NEW World Medical,inc. | 1 | $18 |
| Novartis | 1 | $14 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AcrySof$116
- ORA$116
- AcrySof IQ VIVITY IOL$102
How this compares
$3,760 in reported general payments places this provider in the 65th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 344 | $207,146 |
| RocklatanNetarsudil Mesylat/Latanoprost | 195 | $95,999 |
| RhopressaNetarsudil Mesylate | 184 | $73,836 |
| VyzultaLatanoprostene Bunod | 102 | $53,971 |
| Latanoprost | 3,155 | $40,553 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 151 | $36,711 |
| Alphagan PBrimonidine Tartrate | 64 | $33,882 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 157 | $31,206 |
| RestasisCyclosporine | 26 | $30,038 |
| Travoprost | 161 | $27,450 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 1,393 | $25,895 |
| Prednisolone Acetate | 711 | $25,572 |
| Cyclosporine | 27 | $17,989 |
| Brinzolamide | 84 | $17,921 |
| CombiganBrimonidine Tartrate/Timolol | 43 | $17,716 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Alphagan P, Restasis, Combigan, Restasis Multidose | $578 | $296,480489 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $355 | $169,835379 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $201 | $53,971102 claims |
| AlconSimbrinza | $1,601 | $36,711151 claims |
| NovartisTravatan Z | $14 | $10,52721 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $13 | $3,63124 claims |
| Thea Pharma Inc.Iyuzeh | $20 | $3,62112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in Hemet
- Dagny LuongHemet$1.6M
- Nisha AcharyaSan Francisco$33M
- David WirtaNewport Beach$18.4M
- Michael IpPasadena$10.2M
- Raymond DouglasBeverly Hills$9.7M
- Sherif El HaraziGlendale$9.2M
- Daniel SchwartzSan Francisco$8M
- Nikolas Londonla Jolla$6.1M
- Michael BerlinWest Hollywood$5.7M
- Steven JacobsonLos Angeles$4.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.